I’m part of the Leerink Partners equity research team. Marty Huber, CEO, Mersana: It’s a Jonathan Chang, Equity Research, Leerink Partners: pleasure to host the management team of Mersana.

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Yes, you read that right. The BlackRock CEO fat cat the political right had loved to hate has suddenly become the darling of the MAGA movement following his $22.8 billion purchase of ports from ...

Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development Toxicities continue to pose the most significant challenge in the ...

The ADC wave shows no sign of breaking with the recent approval of ELAHERE for platinum resistant ovarian cancer, Pfizer’s jaw-dropping acquisition of Seagen for $43 billion, and BMS’ $1 ...

After hours: March 10 at 5:42:19 PM EDT Loading Chart for PCSA ...

After hours: March 12 at 7:59:30 p.m. EDT Loading Chart for PFE ...